[{"address1": "Yalelaan 62", "city": "Utrecht", "zip": "3584 CM", "country": "Netherlands", "phone": "31 85 016 3100", "website": "https://www.lavatherapeutics.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "LAVA Therapeutics N.V. operates as a clinical-stage immuno-oncology company that focuses on developing cancer treatments. The company through its Gammabody platform, develops a portfolio of novel bispecific antibodies to engage and leverage the potency and precision of gamma delta T cells to elicit an anti-tumor immune response and enhance outcomes for cancer patients. Its lead clinical-stage candidates are LAVA-1207 that is in Phase 1/2a clinical trial for metastatic castration-resistant prostate cancer. The company is developing other Gammabody drug candidates, which include LAVA-1223, which targets the epidermal growth factor receptor (EGFR) for the treatment of selected solid tumors, as well as LAVA-1266 which are preclinical candidates for the treatment of various hematologic malignancies. The company has a research collaboration and license agreement with Janssen Biotech, Inc. for the potential discovery and development of multi-specific antibody products that are directed to a specified target in various fields of use; and a collaboration with Merck & Co., Inc. to evaluate anti-PD-1 therapy KEYTRUDA in combination with LAVA-1207. LAVA Therapeutics N.V. was incorporated in 2016 and is based in Utrecht, the Netherlands.", "fullTimeEmployees": 34, "companyOfficers": [{"maxAge": 1, "name": "Mr. Stephen Allen Hurly M.B.A., M.Sc.", "age": 56, "title": "CEO, President & Executive Director", "yearBorn": 1968, "fiscalYear": 2024, "totalPay": 826674, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Fred M. Powell CPA", "age": 63, "title": "Chief Financial Officer", "yearBorn": 1961, "fiscalYear": 2024, "totalPay": 582280, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Charles Q. Morris M.D., MBChB, MRCP (UK), Ph.D.", "age": 59, "title": "Chief Medical Officer", "yearBorn": 1965, "fiscalYear": 2024, "totalPay": 655240, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Oxana  Polyakova Ph.D.", "title": "Chief Scientific Officer", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Amy  Garabedian J.D.", "age": 48, "title": "General Counsel & Corporate Secretary", "yearBorn": 1976, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Wouter van Hunnik", "title": "VP & Head of Human Resources", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Hans  van der Vliet M.D., Ph.D.", "age": 49, "title": "Head of Innovation", "yearBorn": 1975, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Ton  Adang Ph.D.", "age": 63, "title": "Chief Development Officer", "yearBorn": 1961, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1735603200, "executiveTeam": [], "maxAge": 86400, "priceHint": 4, "previousClose": 1.24, "open": 1.21, "dayLow": 1.21, "dayHigh": 1.28, "regularMarketPreviousClose": 1.24, "regularMarketOpen": 1.21, "regularMarketDayLow": 1.21, "regularMarketDayHigh": 1.28, "payoutRatio": 0.0, "forwardPE": -0.6443299, "volume": 13335, "regularMarketVolume": 13335, "averageVolume": 412612, "averageVolume10days": 38410, "averageDailyVolume10Day": 38410, "bid": 0.8928, "ask": 1.6, "bidSize": 2, "askSize": 2, "marketCap": 32881624, "fiftyTwoWeekLow": 0.85, "fiftyTwoWeekHigh": 2.81, "priceToSalesTrailing12Months": 6.589504, "fiftyDayAverage": 1.26848, "twoHundredDayAverage": 1.423445, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": -32629282, "profitMargins": 0.0, "floatShares": 10460405, "sharesOutstanding": 26305300, "sharesShort": 106138, "sharesShortPriorMonth": 137072, "sharesShortPreviousMonthDate": 1743379200, "dateShortInterest": 1745971200, "sharesPercentSharesOut": 0.004, "heldPercentInsiders": 0.32693002, "heldPercentInstitutions": 0.36957002, "shortRatio": 1.88, "shortPercentOfFloat": 0.0066000004, "impliedSharesOutstanding": 26305300, "bookValue": 0.959, "priceToBook": 1.303441, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1743379200, "netIncomeToCommon": -27985000, "trailingEps": -0.94, "forwardEps": -1.94, "enterpriseToRevenue": -6.539, "enterpriseToEbitda": 1.056, "52WeekChange": -0.5333333, "SandP52WeekChange": 0.11469197, "quoteType": "EQUITY", "currentPrice": 1.25, "targetHighPrice": 2.990508, "targetLowPrice": 1.030709, "targetMeanPrice": 1.8414294, "targetMedianPrice": 1.5030708, "recommendationMean": 2.5, "recommendationKey": "buy", "numberOfAnalystOpinions": 3, "totalCash": 66557000, "totalCashPerShare": 2.475, "ebitda": -30905250, "totalDebt": 312000, "quickRatio": 6.421, "currentRatio": 6.732, "totalRevenue": 4990000, "debtToEquity": 1.21, "revenuePerShare": 0.186, "returnOnAssets": -0.23016001, "returnOnEquity": -0.73212, "grossProfits": -19560000, "grossMargins": 0.0, "ebitdaMargins": 0.0, "operatingMargins": -6.28156, "financialCurrency": "USD", "symbol": "LVTX", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Delayed Quote", "triggerable": true, "customPriceAlertConfidence": "HIGH", "exchange": "NMS", "messageBoardId": "finmb_546792242", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EDT", "gmtOffSetMilliseconds": -14400000, "market": "us_market", "esgPopulated": false, "shortName": "LAVA Therapeutics N.V.", "longName": "LAVA Therapeutics N.V.", "epsTrailingTwelveMonths": -0.94, "epsForward": -1.94, "epsCurrentYear": -0.786, "priceEpsCurrentYear": -1.5903307, "fiftyDayAverageChange": -0.018479943, "fiftyDayAverageChangePercent": -0.014568574, "twoHundredDayAverageChange": -0.17344499, "twoHundredDayAverageChangePercent": -0.12184875, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "ipoExpectedDate": "2021-03-25", "prevName": "Lava Therapeutics B.V.", "nameChangeDate": "2025-05-16", "averageAnalystRating": "2.5 - Buy", "cryptoTradeable": false, "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 1616765400000, "regularMarketChange": 0.00999999, "regularMarketDayRange": "1.21 - 1.28", "fullExchangeName": "NasdaqGS", "averageDailyVolume3Month": 412612, "fiftyTwoWeekLowChange": 0.39999998, "fiftyTwoWeekLowChangePercent": 0.4705882, "fiftyTwoWeekRange": "0.85 - 2.81", "fiftyTwoWeekHighChange": -1.56, "fiftyTwoWeekHighChangePercent": -0.5551601, "fiftyTwoWeekChangePercent": -53.33333, "earningsTimestamp": 1747222200, "earningsTimestampStart": 1747222200, "earningsTimestampEnd": 1747222200, "isEarningsDateEstimate": false, "marketState": "CLOSED", "regularMarketChangePercent": 0.80645084, "regularMarketPrice": 1.25, "corporateActions": [], "regularMarketTime": 1747425600, "displayName": "LAVA Therapeutics", "trailingPegRatio": null, "__fetch_time": "2025-05-17"}]